2011/01/31 by Winfred C. Wang, Winfred Wang, Carlo Brugnara +21 · 40 citations
Medicine · #Alternative medicine #Clinical endpoint #Disease #Double blinded #Gastroenterology #Hemoglobinopathies and Related Disorders #Hydroxycarbamide #Internal medicine #Iron Metabolism and Disorders #Magnesium #Medicine #Myeloproliferative Neoplasms: Diagnosis and Treatment #Pathology #Placebo #Randomization #Randomized controlled trial #Surgery
paper · pdf · doi:10.1111/j.1365-2141.2010.08523.x
published in British Journal of Haematology 152(6), 771-776 (Wiley)
openalex publication_date 2011/01/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.